Allogene Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €325.72M +135.6% -€3.08M -98.1% -0.9% +1.1 pp -€88.74M -8.8% -27.2% +0.43 pp
    (estimated) €138.26M +463.3% -€159.27M -23.4% -115.2% +7.3 pp -€97.36M -41.8% -70.4% +6.1 pp
    (estimated) €24.55M +142,350.0% -€207.82M +8.8% -846.7% +11K pp -€167.14M +2.1% -680.9% +9.5K pp
    (estimated) €17.23K +∞% -€190.93M +5.1% -1,108,050.0% -11K pp -€163.69M -2.8% -950,000.0% -9.5K pp
    (estimated) €0.00 -100.0% -€181.69M -18.1% N/A -€168.43M -2.1% N/A
    €18.95K -76.8% -€221.93M -21.3% -1,170,863.6% -8.3K pp -€171.97M -15.5% -907,300.0% -6.6K pp
    €81.85K -39.1% -€281.95M -3.9% -344,489.5% -1.3K pp -€203.51M +9.7% -248,649.5% -1.1K pp
    €134.40K -99.9% -€293.28M +87.0% -218,214.1% -2.2K pp -€185.52M +31.8% -138,030.8% -1.4K pp
    €98.29M +∞% -€156.85M -27.2% -159.6% -1.6 pp -€140.75M +232.5% -143.2% -1.4 pp
    €0.00 +NaN% -€215.58M +35.6% N/A -€42.33M -43.2% N/A
    €0.00 +NaN% -€159.04M -12.7% N/A -€74.57M +109.0% N/A
    €0.00 +NaN% -€182.22M +10,575,150.0% N/A -€35.68M -∞% N/A
    €0.00 -€1.72K N/A €0.00 N/A

    Notifications